Adoptive T-cell therapy for cancer: Boutique therapy or treatment modality?

Clinical Cancer Research

Volumn 19, Issue 17, 2013, Pages 4550-4552

  Yee, Cassian ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL EXPANSION; HUMAN; INTENTION TO TREAT ANALYSIS; LYMPHOCYTE TRANSFER; MELANOMA; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; WHOLE BODY RADIATION;

ADOPTIVE TRANSFER; CELL- AND TISSUE-BASED THERAPY; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA;

EID: 84883469566     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1367     Document Type: Article

References (12)

1. BesserMJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel D, Levy D, et al. Adoptive transfer of tumor infiltrating lymphocytes in metastatic melanoma patients: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res 2013;19:4792-800.
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
3. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988;319:1676-80. (Pubitemid 19015247)
4. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, et al. Treatment of metastatic melanoma with autologous CD4 + T cells against NY-ESO-1. N Engl J Med 2008;358:2698-703. (Pubitemid 351860862)
5. Butler MO, Friedlander P, Milstein MI, Mooney MM, Metzler G, Murray AP, et al. Establishment of antitumor memory in humans using in vitro-educated CD8 + T cells. Sci Transl Med 2011;3:80ra34.
6. Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, Lai IP, Dowdy K, et al. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A 2012;109:4592-7.
7. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509 -18.
8. Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 2005;175:2261 -9.
9. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17:4550-7.
10. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 2012;18:6758-70.
11. Schwartzentruber DJ, Hom SS, Dadmarz R, White DE, Yannelli JR, Steinberg SM, et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol 1994;12:1475-83. (Pubitemid 24206248)
12. Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother 2008;31:742-51.